Anacetrapib
Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
Product Specifications
CAS Number
875446-37-0
Product Name Alternative
MK-0859
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PCSK9
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Anacetrapib.html
Purity
99.25
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C1O[C@@H]([C@@H](N1CC2=CC(C(F)(F)F)=CC=C2C3=CC(C(C)C)=C(C=C3OC)F)C)C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4
Molecular Formula
C30H25F10NO3
Molecular Weight
637.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51 (12), 3443-3454.|[2]Dong B, et al. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014 Aug;235 (2) :449-62.|[3]Tan EY, et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos. 2010, 38 (3), 459-473.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15084146 1 Vial
Lentiviral human ADGRF2 shRNA (UAS) - Lentiviral human ADGRF2 shRNA (UAS, iRFP) (25)
Sign In for Pricing
View Details 
orb2875241 100 µL
Delta Opioid Receptor Rabbit pAb, IRDye 800CW conjugated
Sign In for Pricing
View Details 